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In this issue, Culley et al. (1) present findings from an in-
fant mouse model of respiratory syncitial virus (RSV) in-
fection, which provides a new perspective on the patho-
genesis of RSV-mediated lung disease in early life. RSV is
one of the most common respiratory pathogens encoun-
tered in pediatric practice, and virtually all children experi-
ence one or more infectious episodes by the age of 2 yr (2).
The initial focus of the infection is the nasopharyngeal epi-
thelium, and in the majority of cases it remains localized to
this area and the symptomatology is restricted to a runny
nose. In a subset of subjects, however, the virus spreads to
the lower respiratory tract, resulting in a wheezing illness or
acute bronchiolitis that requires hospitalization. Between
50 and 90% of hospitalizations for bronchiolitis amongst
children in the U.S. are directly attributable to RSV and
substantial increases have been documented recently in ad-
missions in North America (2), paralleling the spiralling in-
crease which is occurring in asthma in pediatric and adult
populations throughout the developed world. A possible
causal link between RSV-induced wheeze in infancy and
later development of persistent asthma has been widely de-
bated in this field, and elucidation of the factor(s) responsi-
ble for susceptibility to these apparently related diseases is
considered a matter of urgent priority in pulmonary medi-
cine. However, the precise nature of this linkage is increas-
ingly controversial, as discussed below.
 
Immunopathogenesis of RSV Infection.
 
A typical pattern of
inflammation accompanies RSV bronchiolitis, which includes
epithelial sloughing in the small airways accompanied by hy-
persecretion of mucus and edema, resulting in extensive hyper-
inflation, airflow obstruction, and cough and wheeze (2). Stud-
ies in infected adults indicate that tissue repair is apparent
within days after the onset of symptoms, but restoration of cili-
ated airway epithelial cells takes several weeks, a period during
which symptoms of cough, wheeze, and altered lung function
commonly persist (3). It is noteworthy, however, that virus
elimination and tissue recovery is not accompanied by pro-
longed resistance to RSV, as rapid reinfection is common
amongst both infants and adults (2).
Studies on nasal secretion in children with RSV suggest
that both eosinophils and neutrophils contribute to tissue
damage during infection (4, 5), and the participation of
these cells in the host response appears due in part to virus-
induced secretion of chemokines from infected airway epi-
thelial cells (6). However, studies in animal model systems
point also to a key role for T cells in the immunopathogen-
esis of RSV-induced airways inflammation. In particular,
the Balb/C mouse model has provided valuable insight into
 
potential mechanisms by which CD4
 
 
 
 T cells responding
to RSV-specific antigens may elicit Th2-polarized re-
sponses, which are rarely encountered in viral infections.
Using recombinant vaccinia viruses expressing individual
RSV proteins to prime mice before infection, Culley and
colleagues (7) demonstrated that the responses of CD4
 
 
 
 T
cells from infected animals which were directed against the
surface G-protein of RSV were strongly Th2 polarized,
and elicited prominent pulmonary eosinophilia. These re-
 
sponses involved a dominant population of V
 
 
 
-14 T cells
specific for the 183–197 epitope of the G-protein and were
restricted to certain strains of mice (7, 8), highlighting the
importance of background genetics.
Further studies in the Balb/C model have implicated a
population of IFN-
 
 
 
–secreting CD8
 
 
 
 T cells (9) which
potentially may attenuate the pathogenic Th2 component
of the host response to the G-protein. It is of interest to
note in this context a recent report demonstrating direct
RSV-mediated inhibition of expression of effector activity
by activated RSV-specific CD8
 
 
 
 T cells, via interference
with TCR-mediated signaling (10). Effector activity in-
cluded secretion of IFN-
 
 
 
, and this mechanism thus pro-
vides a potential route for subversion of the Th2 inhibitory
effects of the CD8
 
 
 
 T cell population described previously
(10). It additionally provides a partial explanation for the
short-lived nature of postinfection resistance to RSV via
impairment of CD8
 
 
 
 T cell memory development.
The central importance of cellular (as opposed to humoral)
immune memory in resistance to RSV infection may also be
inferred from the observation that the highest incidence of se-
vere RSV disease occurs in early infancy, during which titres of
maternal antibody are highest. Moreover, infected children
with impaired cellular immune function show prolonged shed-
ding of RSV and high susceptibility to development of RSV
pneumonia (11). However, the potentially pathogenic nature
 
Address correspondence to Prof. P.G. Holt, Division of Cell Biology,
Telethon Institute for Child Health Research, PO Box 855, West Perth,
 
WA 6872, Australia. Phone: 61-8-9489-7838; Fax: 61-8-9489-7707;
E-mail: patrick@ichr.uwa.edu.au 
1272
 
Commentary
 
of RSV-specific cellular immunity was tragically revealed in
trials with formalin-inactivated RSV vaccine in the 1960s in
which 80% of vaccinees required hospitalisation post infection,
and two deaths ensued, with microscopic evidence of intense
infiltrates of mononuclear cells, neutrophils, and eosinophils in
the lungs (12).
 
Epidemiological Findings: The Link with Atopy and Asthma.
 
A variety of epidemiological studies, both cross-sectional and
prospective, suggest possible linkages between RSV infection
in early childhood and subsequent manifestations of atopy and
persistent asthma. Prototypical of these, Sigurs et al. (13) fol-
lowed a population of children after hospitalization for RSV
bronchiolitis during infancy, together with matched uninfected
controls, and reported a 3.5-fold excess in allergy and a 
 
 
 
10-
fold excess of asthma in the postinfected population 3 yr later.
Of particular interest was the observation that risk for asthma
development after RSV infection was much higher in children
with a positive family history (and hence at high genetic risk) of
allergy (13). More recent prospective cohort studies from Stein
and colleagues (14) indicate that the increased risk for asthma
after RSV infection in infancy persists for 10–11 yr.
In relation to the mechanism(s) underlying the association
between early RSV infection and subsequent development of
asthma, one of the prevailing theories posits indirect stimula-
tion of the disease process via promotion of sensitization to in-
halant allergens, as a result of the intrinsically “Th2-trophic” ef-
fects of the virus (7). Recent studies (for a review, see reference
15) indicate that development of long-term T cell memory
specific for these allergens typically occurs during early child-
hood, bracketing the period during which RSV infection is
most frequent. This raises the possibility that bystander stimula-
tion of ongoing T cell responses to inhalant allergens by inter-
mittent RSV infections, through the triggering of local Th2
cytokine production in the airway mucosa (7, 8), may tip the
balance toward consolidation of Th2-polarized memory against
the allergens, thus setting the scene for subsequent atopic
asthma. While there is some evidence for promotion of sensiti-
zation to allergens after RSV infection from small in vitro stud-
ies on T cell function in PBMCs from children, results from
large scale epidemiological studies have not confirmed these
findings, and instead argue that the “asthma-promoting” effects
of RSV infection in childhood are independent of atopy (14).
It should be emphasized, however, that the association be-
tween atopy and asthma has been a consistent finding over a
wide range of studies, and moreover that the strongest asthma-
promoting effects of atopy are observed in association with
early onset of sensitization to inhalant allergens (for a review,
see reference 15).
Similar conclusions follow from other large prospective
cohort studies that have documented episodes of infection-
associated wheezing bronchiolitis in infancy without iden-
tification of relevant pathogens, and have correlated the
frequency of these episodes with risk for subsequent devel-
opment of persistent asthma. In one such prospective study
from our center on 2,602 children, 
 
 
 
2 episodes of wheez-
ing lower respiratory illness during the first year of life in-
creased the risk for current asthma at 6 yr of age fourfold in
nonatopics and ninefold in atopics, but did not increase risk
 
for atopy per se (16). In our view these findings suggest that
the effects of severe respiratory viral infections and atopy
upon risk for asthma are mediated via independent causal
pathways, and further that these effects can interact in a
synergistic fashion in driving asthma development (further
discussion below).
It is additionally noteworthy that infections with other
viruses, in particular rhinoviruses, have been identified as
major triggers of asthma exacerbations in school children
with established (usually atopic) asthma (17). Furthermore,
respiratory infection with viruses other than RSV is recog-
nized as a major aetiologic factor in nonatopic (or intrinsic)
asthma in adults, and this form of asthma also manifests a
Th2-like “signature” in the form of eosinophil involve-
ment at lesional sites in the airway mucosa (18).
In summary, it appears that while a strong case can be
made for early RSV infection as a risk factor for asthma de-
velopment in childhood, particularly in combination with
atopy, current perceptions of the underlying mechanisms,
which emphasize the importance of the unique Th2-
trophic properties of this virus, do not in our view provide
a satisfactory explanation for many of the available findings.
However, recent studies focusing on the late stage develop-
ment of innate and immune function in the immediate
postnatal period, including the report in this issue of 
 
The
Journal of Experimental Medicine
 
 by Culley et al. (1), shed
fresh light on this complex problem.
 
Ontogeny of Immune Function: Kinetics of Postnatal Matura-
tion of Immune Competence as a Determinant of Disease Suscep-
tibility during Early Life.
 
It is now recognized that immune
function(s) in the fetal compartment are attenuated relative to
postnatal life, and that the attenuation is most marked with re-
spect to capacity to generate Th1 cytokines, which are highly
toxic to the placenta (19). This Th2 “skew” is maintained via a
series of multilayered control mechanisms operative both within
the innate immune system (in particular via preferential down-
regulation of IL-12p35 gene expression in neonatal dendritic
cells, reference 20) and in the T cell system (e.g., CpG hy-
permethylation in the IFN-
 
 
 
 promoter in neonatal CD4
 
 
 
CD45RA
 
 
 
 T cells (21).
It is additionally clear that the principal trigger(s) for late-
stage functional maturation of the immune system are micro-
bially derived molecules not normally encountered in fetal life,
which signal via specific TOLL receptors and CD-14. How-
ever, it is also evident that the rate at which the immune sys-
tem in newborns progresses from the Th2-skewed state char-
acteristic of the fetal compartment, to the more balanced (by
comparison more Th1-polarized) adult-equivalent state, is
highly variable within the human population, particularly with
respect to capacity to produce Th1-associated cytokines such
as IFN-
 
 
 
 (22) and also IL-12 (23).
Studies from our group and others (for a review, see refer-
ence 15, 16) have demonstrated that atopic family history pos-
itive (AFH
 
 
 
) children at high genetic risk of atopy and asthma
exhibit slower rates of postnatal maturation of Th1 compe-
tence than the population at large. The genetic mechanisms
underlying these variations in Th1 functional capacity amongst
children are incompletely understood, but appear to involve 
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inter alia polymorphisms in CD-14 (24) and also IL-12 (25),
the former being associated with severity of atopy, and the lat-
ter with severity of asthma.
It is widely acknowledged in the epidemiological litera-
ture that early postnatal life represents a period of height-
ened risk for infectious disease, and also for allergic sensiti-
zation, and the accumulating evidence strongly suggests
that a generalized maturational deficit in Th1 function un-
derlies this susceptible state. The findings indicating that
this deficit is further exaggerated in children genetically at
high risk of atopy (15, 16) provide a plausible explanation
for their increased propensity to default to the Th2 path-
way during development of Th memory against aeroaller-
gens. It also explains the increased Th2 polarity of their re-
sponses to vaccine antigens (16, 22).
Given the importance of cellular immunity in limiting
RSV shedding during early infection (11), it is highly likely
that reduced Th1 function during this life phase plays a
central role in susceptibility to bronchiolitis after RSV in-
fection. This possibility is supported by indirect evidence
from several studies suggesting an association between this
syndrome and attenuated capacity to mount systemic IFN-
 
 
 
and IL-12 responses (for a review, see reference 15), and
in particular by the recent finding that the most severe
manifestation of acute RSV bronchiolitis in infants are as-
sociated with markedly reduced local production of IFN-
 
 
 
in airway secretions (26).
In this issue, Culley and colleagues (1) provide compelling
new evidence which further emphasizes the importance of is-
sues related to postnatal development of immune function as
determinants of susceptibility to RSV bronchiolitis, and ulti-
mately atopy and asthma. They demonstrate that in the Balb/C
mouse model, the timing of first infection with RSV deter-
mines the polarity of RSV-specific immunological memory
which develops, and this in turn influences the severity and na-
ture of the disease after subsequent reinfections. A plausible in-
terpretation of their findings is that if animals are initially in-
fected during early infancy while their capacity to express Th1
immunity is developmentally constrained, they generate Th2-
polarized RSV-specific immunological memory, which upon
reinfection as adults is expressed in the form of intense infiltrates
of eosinophils and IL-4–secreting CD4
 
 
 
 Th2 cells in the lung.
In contrast, if initial infection is delayed for several weeks thus
enabling maturation of immune function, the ensuing CD4
 
 
 
Th-memory which develops is Th1-polarized, and both pri-
mary (and subsequently secondary) immune responses to the
infection lack the pathogenic component of lung eosinophilia.
As an aside, these findings raise considerable questions about
the commonly used animal models of allergic inflammation,
which feature sensitization and challenge of adult mice with
mature immune systems, whereas in the human situation initial
allergen exposure occurs in early life.
Culley’s findings, if directly applicable to human infants,
have important theoretical implications for the design of
future treatment strategies for acute RSV bronchiolitis,
and also for development of prophylactic approaches
which aim the break the nexus between infantile bronchi-
olitis and subsequent asthma. In the scenario depicted in
 
Fig. 1, the sequelae of RSV infection during infancy are
determined by the level of maturation/competence of the
immune system at the time of first infection (1). Thus, if
initial RSV infection occurs beyond infancy at a time
when postnatal maturation of adaptive immune function(s)
is well progressed, Th1-polarized host defense mechanisms
will be triggered, leading to rapid resolution of the primary
infection, and accelerated protection against secondary in-
fection via generation of Th1-polarized memory. In con-
trast, infection occurring early in infancy (
 
 
 
1 yr of age)
when the immune system is still in the fetal-like, Th2-
skewed state, will have a high likelihood of triggering
Th2-polarized primary immunity, with attendant risk of
spread to the lower respiratory tract and development of
acute wheeze. Primary RSV infection at this early age also
carries the additional risk of development of RSV-specific
Th2-polarized immunological memory, which may render
the effects of subsequent infections even more severe by
blunting capacity for Th1-mediated defences, and by fur-
ther enhancing the Th2 (in particular eosinophilic) com-
ponent of the host response to the virus. The likelihood of
developing initial Th2-polarized immunity to RSV infec-
tion during infancy will be further heightened in AFH
 
 
 
children at high genetic risk of atopy, in whom this normal
developmental deficit in Th1 function is exaggerated. The
worst case scenario, in which an AFH
 
 
 
 infant develops
sensitization to inhalant allergens and additionally experi-
ences repeated RSV infections commencing in early in-
fancy (wheezing lower respiratory illnesses; wLRI in Fig.
1), is illustrated as the synergism resulting from the conflu-
ence of these two pathways, as predicted by the sliding
scale of Odds Ratios for asthma in infected and/or atopic
children in the inset in Fig. 1.
While this scheme provides a biologically plausible
model for integration of many of the key findings from
the mouse RSV model with the relevant human asthma
and allergy literature, a number of specific issues remain to
be resolved. First, the role of maternal antibody requires
clarification. The epidemiological literature indicates that
risk for RSV bronchiolitis peak between 2 and 6 mo of
age, and it is plausible that mild (often subclinical) infec-
tions may be occurring very early in infancy, which are
prevented from spreading beyond the upper respiratory
tract by maternal antibody, but which nevertheless co-
vertly “prime” the Th2-polarized immune system aided
by the adjuvant effect of the maternal antibodies. Second,
the sequelae of perinatal RSV priming revealed in the
mouse (1) need to be balanced against findings discussed
above which point to the relatively short-lived nature of
RSV-specific Th-memory in both children and adults.
However, it remains possible that in some subjects, the
Th2-polarized RSV-specific Th-memory which develops
during early infections may persist into later life, in some
cases into adulthood. In this context, it is also important to
consider the potential contributions of other viruses. For
example, bronchiolitis resulting from parainfluenza type 3
infection, like RSV bronchiolitis, occurs primarily in the
first 6 mo of life, but with a lower frequency (3). How- 
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ever, parainfluenza types 1–3 are a frequent cause of other
respiratory illnesses which do not require hospitalisation,
and may covertly contribute to airway damage via the
model in Fig. 1, albeit at a lower intensity than RSV. Re-
cent findings implicating metapneumovirus as a cause of
severe bronchiolitis in young children (27) raise the possi-
ble involvement of a potentially growing range of other
viruses in this process. Finally, as noted above, airway
biopsy samples from adults with nonatopic (intrinsic)
asthma, in which virus infection is viewed as a major trig-
ger, also display evidence of activated Th2 cells and eosin-
ophils (18), suggesting local expression of Th1-polarized
memory against the triggering virus.
Many of these issues can only be resolved by more detailed
and targeted prospective studies in humans, but as illustrated in
the publication from Culley et al. (1), the mouse model has
unique potential to yield specific information to help sharpen
the focus of the human studies. Importantly, their findings also
highlight the necessity for studying RSV-mediated disease and
its sequelae in the specific developmental context in which the
infection primarily manifests in its human host.
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